29 August

• At 00:01 – European Journal of Preventive Cardiology – Cost-Effectiveness of a Digitally Enabled Cardiac Rehabilitation Program for patients with Coronary Heart Disease – Justin Braver
• At 00:01 – European Journal of Preventive Cardiology – Lipid-lowering drug treatment and mortality among individuals ≥75 years without cardiovascular disease: a population-based cohort study – Jiayue Zhang
• At 00:01 – European Journal of Preventive Cardiology – Impact of a pneumococcal vaccination incentive campaign in chronic heart failure patients in France: a cluster-randomized trial – François Roubille
• At 08:15 – European Heart Journal – Atlas of interventional cardiology 2023: European Society of Cardiology and European Association of Percutaneous Coronary Interventions – Eric Van Belle
• At 08:45 – European Heart Journal – Quiet Flames: Inflammation Without Traditional Risk Factors – Wolfgang Koenig
• At 08:45 – European Heart Journal – C-Reactive Protein and Cardiovascular Risk Among 12,530 Women with No Standard Modifiable Risk Factors: The “SMuRF-Less but Inflamed” Women’s Health Sub-Study – Paul Ridker
• At 09:00 – European Heart Journal – A new journal for the cardiovascular community: European Heart Journal – Valvular and Structural Heart Disease – Judith Ozkan
• At 10:00 – European Heart Journal – Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure – Fernando Dominguez
• At 10:00 – European Heart Journal - Cardiovascular Imaging – Hypercontractile phenotype in hypertrophic cardiomyopathy indicates unfavorable hemodynamics, coronary flow and prognosis – Karina Alicja Wierzbowska-Drabik
• At 11:15 – European Heart Journal – Clinical outcomes of transcatheter tricuspid valve replacement stratified by baseline tricuspid regurgitation severity from the TRISCEND II Trial – Philipp Lurz
• At 12:10 – European Heart Journal Open – Transcatheter Versus Surgical Aortic Valve Replacement in Bicuspid Aortic Valve Stenosis – Dharam J. Kumbhani / Joseph Kassab
• At 15:45 – European Journal of Cardiovascular Nursing – Patient perceptions on Lp(a) testing and treatment for secondary prevention of cardiovascular disease (CVD) - results from the INTERASPIRE study in seven countries across six WHO regions – Dr. Catriona Sian Jennings
• At 15:45 – European Journal of Preventive Cardiology – Physician perspectives on Lp(a) testing and management in patients with cardiovascular disease: Interviews from 7 Countries Across 5 WHO Regions From INTERASPIRE – Dr. Jaimini Cegla
• At 16:45 – European Journal of Preventive Cardiology – Smoking and the risk of sudden cardiac arrest in young-aged adults: a Korean nationwide population-based study – Jong II Choi
• At 17:00 – European Heart Journal – The estimated benefit of the early initiation of disease-modifying therapy in community-based patients with suspected heart failure – Kieran Docherty
• At 17:00 – European Heart Journal - Quality of Care and Clinical Outcomes – Applicability of guideline-informing lipid-lowering clinical trials to contemporary real-world patients with atherosclerotic cardiovascular disease – Frank L.J. Visseren
• At 17:15 – European Journal of Preventive Cardiology – Prevalence and prognostic importance of chronic kidney disease in patients with coronary heart disease – Lars Rydén
• At 18:15 – EP Europace – 2-Year Outcomes of Left Bundle Branch Area Pacing Versus Traditional Right Ventricular Pacing in middle-aged Adults: A Registry-Based Trial – Matteo Bertini

30 August

• At 00:01 – European Journal of Preventive Cardiology – Polycystic Ovarian Syndrome and Long-Term Risk of Acute Myocardial Infarction and Ischemic Stroke – Eva Havers-Borgersen
• At 08:15 – European Heart Journal – Incidence, risk & prognostic factors of immune-checkpoint inhibitors cardiomyotoxicities: Results from the French National Health Data System – Joe-Elie Salem
• At 08:30 – European Heart Journal – Improving outcomes after AF ablation by integrated personalized lifestyle interventions: a randomized controlled trial – Jasper Raphaël Vermeer
• At 09:00 – European Heart Journal – Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care – Markus Anker
• At 09:33 - European Journal of Heart Failure - Burst steroid therapy for acute heart failure. The CORTAHF randomized, open label pilot trial - Gad Cotter 
• At 10:15 – European Heart Journal – Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease – Thomas F. Lüscher
• At 10:45 – European Heart Journal – Hypokalemia as a trigger for atrial fibrillation: Insights from patients with implanted loop recorders – Søren Zöga Diederichsen
• At 10:45 – European Heart Journal – Hypokalemia in atrial fibrillation: A red flag for more comprehensive workup? – Dominik Linz
• At 11:00 – European Heart Journal – AAV9-Mediated KCNH2 Suppression-Replacement Gene Therapy in a Transgenic Rabbit Model of Type 1 Short QT Syndrome – Katja E Odening
• At 11:00 – European Heart Journal – Sex differences in the effect of beta blockers after myocardial infarction without reduced ejection fraction: A Pre-specified Analysis from the REBOOT Trial – Borja Ibanez
• At 11:00 – European Journal of Preventive Cardiology – Interplay Between Mental Health, Greenness, and Environmental Factors in Cardiovascular Mortality: Insights from AIR-MIN – Michał Święczkowski
• At 11:15 – European Heart Journal - Cardiovascular Pharmacotherapy – Impact of early in-hospital initiation of sacubitril/valsartan on left ventricular reverse remodelling in acute heart failure – Atsushi Tanaka
• At 13:15 – European Heart Journal – Evaluation of the Performance of Fully Artificial Intelligence Generated vs Human-Authored Abstracts in a Real-World Setting – Karl-Patrik Kresoja
• At 13:15 – European Heart Journal - Cardiovascular Pharmacotherapy – Effectiveness and safety of Rivaroxaban versus Apixaban in patients with Atrial Fibrillation and Peripheral Artery Disease – Christel Renoux
• At 14:00 – European Heart Journal – Bivalent RSV Prefusion F Protein-based Vaccine Effectiveness in Individuals with and without Atherosclerotic Cardiovascular Disease: The DAN-RSV Trial – Tor Biering-Sørensen
• At 14:00 – European Heart Journal – High-Dose versus Standard-Dose Inactivated Influenza Vaccine in Persons with and without Atherosclerotic Cardiovascular Disease: The DANFLU-2 Trial – Tor Biering-Sørensen
• At 14:00 – European Heart Journal – Respiratory Viruses, Vaccines, and the Heart: Lessons from DANFLU-2, DAN-RSV, and Beyond – Bettina Heidecker
• At 15:15 - European Heart Journal - Artificial intelligence-based identification of thin-cap fibroatheromas in relation to clinical outcome: the PECTUS-AI study - Niels Van Royen
• At 15:15 - European Heart Journal -  Artificial intelligence-based identification of thin-cap fibroatheromas: A new paradigm for risk stratification ? - Ik - Kyung Jang
• At 15:30 – Cardiovascular Research – Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study – Subodh Verma
• At 17:00 – European Heart Journal – Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-Difference trial – Ulf Landmesser
• At 17:30 – European Heart Journal – Twice-Daily Aspirin in Patients with Diabetes Mellitus or Aspirin Resistance after Acute Coronary Syndrome – Jean-Guillaume Dillinger
• At 17:30 – European Heart Journal – Benefits and harms of the randomized, clinical controlled Danish Cardiovascular Screening (DANCAVAS) II trial of 60–64-year-old men – Jes S. Lindholt

31 August

• At 00:01 – European Heart Journal - Quality of Care and Clinical Outcomes – Disparities in STEMI Diagnosis and Management Among Patients with Mental Health Conditions – Dorian Garin
• At 00:01 – European Journal of Preventive Cardiology – SCORE2 charts assign a different risk category than the underlying model in a large portion of Polish primary care patients – Marcin Goławski
• At 08:15 – European Heart Journal – Loss of Y chromosome signatures in human cardiovascular disease – Thimoteus Speer
• At 08:15 – European Heart Journal – The Silent Saboteurs: Reticulated Platelets in Coronary Artery Disease – Scott J Cameron
• At 08:15 – European Heart Journal – Semaglutide promotes vascular repair mechanisms in people with cardiometabolic disease: Primary results of the SEMA-VR CardioLink-15 translational study – Subodh Verma
• At 08:15 – European Heart Journal – Reticulated platelets in coronary artery disease: a multidimensional approach unveils prothrombotic signalling and novel therapeutic targets – Dario Bongiovanni
• At 08:15 – European Heart Journal – In vivo CRISPR activation to treat cardiomyopathy caused by a FLNC truncating variant – Enrique Lara-Pezzi
• At 08:51 – European Journal of Heart Failure – Left ventricular ejection fraction and benefit of tricuspid valve interventions – Insights – David Messika-Zeitoun
• At 09:15 – EP Europace – Cost-effectiveness of Apixaban vs Aspirin for the Reduction of Thrombo-Embolism in High-Risk Patients with Device-Detected Atrial Fibrillation: Insights from the ARTESiA trial – Andre Lamy
• At 10:15 – European Heart Journal - Cardiovascular Pharmacotherapy – Clinical Features Modifying the Cardiovascular Benefits of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis – C. Michael Gibson
• At 10:15 – European Heart Journal - Cardiovascular Pharmacotherapy – Long-term effectiveness of ACE inhibitors or angiotensin receptor blockers in myocardial infarction with preserved left ventricular ejection fraction – Anna Humphreys
• At 12:00 – European Heart Journal - Case Reports – Conservative Non-surgical Management of Penetrating Cardiac Injury with Three Retained Metal Nails: A Case Report – Ramtin Khanipour
• At 12:15 – European Heart Journal - Case Reports – Sympathectomy in Refractory Ventricular Arrhythmias in Patients with LVAD: A Ground Round Case Report – Melanie Fernandez Caso
• At 12:30 – European Heart Journal - Case Reports – The use of multimodality imaging in heart transplant recipients: a case series – Kamil Stankowski
• At 12:45 – European Heart Journal - Case Reports – A reconsidered diagnosis in an unresolving myocarditis - a case report – Bradley Woolfenden
• At 13:45 – European Heart Journal – Major cardiovascular events in first-degree relatives to individuals with elevated plasma lipoprotein(a): a registry-based cohort study – Jonas Brinck
• At 15:45 – European Heart Journal - Cardiovascular Imaging – Association between inflammatory biomarkers, chronic stress, and pericoronary adipose tissue attenuation obtained with coronary CT – Aju Pazhenkottil
• At 15:45 – European Heart Journal - Cardiovascular Imaging – Eat, Stress, Inflame: examining the link between chronic stress, coronary inflammation and plaque – Jonathan Weir-McCall
• At 15:55 – European Heart Journal – Serum magnesium and outcomes in patients with heart failure and reduced ejection fraction: Insights from the GALACTIC-HF trial – John JJV McMurray
• At 16:00 – European Heart Journal – The HFpEF-ABA Score to Stratify Heart Failure Severity and Enrich for Elevated Risk in HFpEF: Insights from the SUMMIT Trial – Barry A. Borlaug
• At 16:30 – European Heart Journal – Temporal Modulation of Antiplatelet Therapy in High-Risk Patients Undergoing Complex Percutaneous Coronary Intervention: The TAILORED-CHIP Randomized Clinical Trial – Duk-Woo Park
• At 16:30 – European Heart Journal – Tailored DAPT: Still a Theory in Search of Proof – Davide Capodanno

1 September

• At 00:01 – European Journal of Preventive Cardiology – Heart Failure in Patients with Recently Diagnosed Atrial Fibrillation: Findings from the GLORIA-AF Registry Phase III – Dr. Bernadette Corica
• At 08:15 – European Heart Journal – Impact of vericiguat on mortality in patients with heart failure and reduced ejection fraction: insights from the VICTOR trial – Javed Butler 
• At 11:35 – European Journal of Preventive Cardiology – Apolipoprotein B outperforms low density lipoprotein particle number as a marker of cardiovascular risk in the UK Biobank – Elizabeth Sage Epstein
• At 14:30 – European Heart Journal – Surgical Left Atrial Appendage Occlusion in Patients with Valvular Heart Disease, CHA₂DS₂-VASc No Less Than Two, and No Atrial Fibrillation: One-Year Outcomes of The OPINION Study – Hansong Sun
• At 14:45 – European Heart Journal – Quality of Care and Clinical Outcomes – Effects of anticoagulation in patients with device-detected atrial fibrillation and multiple stroke risk factors: A Win Ratio analysis of the NOAH-AFNET 6 trial – Paulus Kirchhof
• At 15:15 – European Heart Journal – Artificial intelligence-based identification of thin-cap fibroatheromas in relation to clinical outcome: the PECTUS-AI study – Niels van Royen
• At 15:15 – European Heart Journal – Artificial Intelligence-Based Identification of Thin-Cap Fibroatheroma: A New Paradigm for Risk Stratification? – Ik-Kyung Jang
• At 15:15 – European Heart Journal Open – Prognostic Significance of Abdominal Aortic Calcification Scores on DXA Scans for Mortality in Cancer Survivors: NHANES-based cohort study (2013-2019) – Mustafa Al-jarshawi
• At 15:45 – EP Europace – Real-World experience with the Pentaspline Pulsed Field Ablation System One-year outcomes of the FARADISE Registry – Lucas Boersma

2 September

• At 09:00 European Heart Journal — Do Obesity and Visceral Adiposity Promote Heart Failure With Reduced Ejection Fraction? — Milton Packer